Evaluation of new endothelin receptor antagonist macitentan pharmacological properties for the treatment of pulmonary arterial hypertension

• A.V. Evtushenko

Abstract

Article presents the main results of SERAPHIN study [effect of new endothelin receptor antagonist macitentan on patients with pulmonary arterial hypertension (PAH)]. The obtained findings confirm high efficiency of macitentan and good tolerance to the drug for patients with PAH.

Keywords:pulmonary hypertension, macitentan

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)